SCI PHARMTECH, ING.

簡報

procedure Thainform Forwardterium Leola

All-HescoryList.Count > 0 these Forwardten inn, Enchind in Michon

Xol ardAckion, Enabled a False and r

CLOSE EXOTORIC + Teres, NYL !! Store population Prosentern Mobile which I is coast plasp: Dispatch, var MII Reading at OleVariable r-way

d destoryTodes + 01 MALDE HARGOLYLAST COMME . HAR I dioryLift Delate Office or 97 Highlip Ladas in Ristory List. Add

DES

RicertyTodes is Newtodes: ar brownsteads then hegin

Doctor Course I'm Falue.

Mel Andex ; a UEZ; Ituna, Index02

AE MANDICON - - 1 About

UP J. ftems, Promer (0, U914

員工數Employee:275 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣795佰萬元(NTD 795mn) 營業項目Business: 原料藥API(75.14%) 中間體Intermediate(20.76%) 特用化學品 Custom-made chemicals(4.10%)

公司概況Outline

Jan~July, 2020 Sales	Y2019 Sales
52.01%	53.96%
18.75%	14.49%
18.16%	21.33%
7.95%	9.39%
3.13%	0.83%
100.00%	100.00%

Unit: K NTD

	2020.Q1	2020.Q2	2020.H1
營收Sales	784,328	727,922	1,512,250
營業成本COGS	(425, 911)	(346, 449)	(772, 360)
毛利Gross Profit	358,417	381,473	739,890
毛利率 GP Ratio	45.7%	52.4%	48.9%
營業費用Operating Expenses	(78,215)	(86, 273)	(164, 488)
營業利益Operating Income	280,202	295,200	575,402
營業外損益Non-Operating In/Ex	(14, 387)	2,174	(12, 213)
税前淨利 Net Profit before Tax	265,815	297,374	563,189
所得稅Income Tax	(57, 484)	(55,704)	(113, 188)
本期淨利Net Profit after Tax	208,331	241,670	450,001

產品組合-Products

Y2017	%	Y2018	%	Y2019	%
S-MMAA / Dulo	13.14	HOCLQ Sulfate	22.29	VA Series	22.91
VA Series	12.48	VA Series	16.70	S-MMAA /Dulo	15.55
HOCLQ Sulfate	12.47	S-MMAA / Dulo	12.57	PGA	12.45
LPF.Na	9.41	PGA	9.64	HOCLQ	10.32
PGA	9.22	Pent-2 / PEB.Na	6.68	Pent-2 / PEB.Na	6.12
Pent-2 / PEB.Na	8.69	PMDOL / Olivetol	5.80	PMDOL+Olivetol	5.84
5-HMT / 5-Wing	6.26	5-HMT / 5-Wing	2.95	LPF.Na	4.07

Total	71.67	Total	76.63	Total	77.26

SCI PHARMTECH, INC.

Product	$\%$	Jan~July, 2020 Sales (NT\$)
VA series	24.91	448,576,880
HOCLQ Sulfate	23.88	429,997,047
S-MMAA / Dulo.Hcl	13.96	251,403,670
PGA	10.51	189, 205, 283
Pent-2 / PEB.Na	6.25	112,622,147
BZA	4.08	73,443,599
Olivetol / PMDOL / OL-COOEt	2.87	51,655,975
PF.Hcl	2.62	47,198,454

VA Series:

Valproic Acid, Divalproex Sodium, Sodium Valproate

適應症 Application: 癲癇(seizure)、躁鬱症(bipolar disorder)、偏頭痛(migraine headaches)

S-MMAA / Duloxetine HCl

適應症 Application: 重鬱症(major depressive disorder)、廣泛性焦慮症 (generalized anxiety disorder) 、糖尿病週邊神經痛 (diabetic neuropathy) 、纖維肌痛(Fibromyalgia)、慢性腰痛(日本地區) lower back pain (only in Japan)

Pyrogallolaldehyde ( PGA)

Benserazide 治療帕金森氏症之中間體 Intermediate for Parkinson's Disease

Hydroxychloroquine sulfate

適應症 Application: 類風濕性關節炎(rheumatoid arthritis) 、瘧疾 (malaria)、慢性多形性日光疹、慢性圓板狀紅斑症 (discoid and systemic lupus erythematosus)

Pent-2 / Pentobarbital Sodium

鎮定安眠用中間體及原料藥 Intermediate and API for calmative

Menthadienol, Olivetol, Ethyl Olivetolate

為Dronabinol (THC 四氫大麻酚)及Cannabidiol (CBD大麻二酚) 之關鍵中間體 The key intermediates for Dronabinol (THC) and Cannabidiol (CBD)
THC 適應症 Applications:
化療引起的噁心、嘔吐 Nausea and vomiting due to chemotherapy
愛滋病引起之厭食症 anorexia due to AIDS
CBD 適應症 Applications:
Epidiolex:兒童罕見癲癇以及多發性硬化症 For seizures in patients aged 2 years and older, and Multiple Sclerosis.

CBD (Cannabidiol)

CBD之應用廣泛:從癲癇、巴金森氏症、阿茲海默症,到關節炎、躁鬱、焦慮、失眠、止痛、抗發炎等。
市場預估:
美國市場:2020年預估值為美金290億 ? 全球大麻與其衍生物之應用(醫藥、保健、美容等):美金兩千億?

旭富 CBD (Cannabidiol)

製程放大成功,12月取得外銷專用許可證
2020年初完成確效,申請製藥許可證及美國藥證 (US DMF)
開始業務開發與小量試銷

CBD (Cannabidiol)

Wide range of medical benefits, from epilepsy, Parkinson's and Alzheimer's disease, bipolar disorder, anxiety, pain, inflammation, to arthritis, insomnia, etc.
Market estimations:

US market: US\$ 29 billions in 2020?

Total Cannabis Opportunity (pharmaceutical, nutraceutical, beauty, etc.): ~ US\$ 200 billions ??

CBD (Cannabidiol) by SCI

Scale-up successfully, to obtain export license in Dec. 2019.
To complete validation by early 2020, to apply domestic license with TFDA and to file US DMF.
BD started, qualification / trials on-going.

SCI PHARMTECH, INC.

No.	API	DMF (USA)	CEP (EDQM)	MF (Japan)	DMF (Canada)	CGMP certified (TFDA)
$\overline{1}$	Valproic Acid	2003	2004	2008	2008	2003
2 ¹	Probucol	2004		2017	2015	2015
3 ¹	Divalproex Sodium	2005			2010	2005
$\overline{4}$	Propafenone Hydrochloride	2010	2012	2012	2012	2010
5 ⁵	Duloxetine Hydrochloride	2011	2014	2017	2016	2012
6 ^°	Allopurinol	2011	2003			2004
$\overline{7}$	Clindamycin Palmitate HCI	2011
8	Articaine Hydrochloride	2014	2014			2013
9 ^°	Hydroxychloroquine Sulfate	2014			2014	2014
10	Brinzolamide	2015		2017		2015
11	Sodium Valproate		2006	2017		2004
12	Pentobarbital Sodium		2011			2009
13	Methylphenidate HCI		2014			2011
14	Bisoprolol Fumarate					2006
15	Thiopental acid					2012
16	Loxoprofen Sodium Hydrate			2011		2012
17	Atomoxetine HCI					2016

SCI

AI assistant

SCI Interim / Quarterly Report 2020

52383_rns_2020-08-20_d6beadb6-b9ab-42f9-a55b-427d3cf7c7b5.pdf